Eli Lilly unveiled a new Zepbound delivery system as its main rival absorbed fresh clinical and stock-market blows.
Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...
Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...
New customers can save $100 on their month of GLP-1 treatments at Regenics. Find out how it works and how to get started today.
Popular GLP-1 weight-loss medications have helped millions of people shed pounds, but new research from Australia.
Over the long term, Levin expects oral GLP-1s to gain favor over injectables. Most patients prefer pills to injections, and ...
Demand from patients for obesity medication is unrelenting. So, too, is the battle over who gets to develop and distribute ...
A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, ...
A Novo Nordisk-led study comparing CagriSema, its GLP-1 drug candidate for obesity, found that Eli Lilly’s Zepbound resulted in greater weight loss. The open-label, head-to-head trial analyzed the ...
Lilly launches four-dose Zepbound KwikPen in the US. Self-pay starter price begins at $299 per month. Move aims to improve ...
Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results